Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Dec;113(12):1927-34.
doi: 10.1007/s00702-006-0487-5. Epub 2006 Jun 1.

Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro

Affiliations
Comparative Study

Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro

A G Ludolph et al. J Neural Transm (Vienna). 2006 Dec.

Abstract

Methylphenidate (MPH) is the most common used drug in child and adolescent psychiatry. Despite of this fact, however, little is known about its exact pharmacological mechanisms. Here we investigated the toxic effects of MPH in vitro in human embryonic kidney (HEK-293) cells stably expressing the human dopamine transporter (HEK-hDAT cells) and in cultured rat embryonic (E14.5) mesencephalic cultures. MPH alone (up to 1 mM) affected neither the growth of HEK-hDAT cells nor the survival of dopaminergic (DA) neurons in primary cultures after treatment up to 72 h. No differences in neuronal arborisation or in the density of synapses were detected. 1-methyl-4-phenylpyridinium (MPP(+)) showed no toxic effect in HEK-293 cells, but had significant toxic effects in HEK-hDAT cells and DA neurons. MPH (1 microM - 1 mM) dose-dependently reduced this cytotoxicity in HEK-hDAT cells and primary mesencephalic DA neurons. The presented results show that application of MPH alone does not have any toxic effect on DA cells in vitro. The neurotoxic effects of MPP(+) could be significantly reduced by co-application of MPH, an effect that is most likely explained by MPH blocking the DAT.

PubMed Disclaimer

References

    1. Eur J Pharmacol. 1991 Dec 12;208(4):273-86 - PubMed
    1. Prog Drug Res. 2002;59:111-31 - PubMed
    1. Biochem Pharmacol. 2002 Mar 1;63(5):909-20 - PubMed
    1. Can J Psychiatry. 2004 Nov;49(11):761-8 - PubMed
    1. JAMA. 2000 Feb 23;283(8):1025-30 - PubMed

Publication types

MeSH terms

LinkOut - more resources